Predicting response to carvedilol for the treatment of heart failure: A multivariate retrospective analysis

被引:31
作者
Schleman, KA
Lindenfeld, JA
Lowes, BD
Bristow, MR
Ferguson, D
Wolfel, EE
Abraham, WT
Zisman, LS
机构
[1] Albany Med Ctr, Heart Inst MC55, Albany, NY 12208 USA
[2] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[3] Univ Kentucky, Lexington, KY 40506 USA
关键词
beta-blocker; cardiomyopathy; myocardium;
D O I
10.1054/jcaf.2001.22491
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: Carvedilol has been shown to decrease the progression of heart failure and improve left ventricular function and survival in patients with a left ventricular ejection fraction (LVEF) less than 35%, However, not all patients respond uniformly to this therapy. We proposed to identify variables that could, potentially, be used to predict response to carvedilol therapy as measured by the change in LVEF after treatment (Delta LVEF), and to identify pretreatment variables associated with hospitalization for heart failure after carvedilol therapy. Methods and Results: A retrospective analysis of 98 patients treated with open-label carvedilol for a mean period of 16 months was performed by using bivariate and step-wise multivariate analyses. Bivariate analysis showed a positive correlation of Delta LVEF with heart rate at baseline (P = .001). There was a negative correlation of Delta LVEF with baseline LVEF (P < .01), diabetes mellitus (P = .04), and ischemic cardiomyopathy (P = .0002). Multivariate analysis showed a positive correlation of <Delta>LVEF with heart rate at baseline (P = .01) and a negative correlation with initial LVEF (P = .02) and ischemic cardiomyopathy (P = .006). Variables associated with hospitalization after initiation of carvedilol therapy were New York Heart Association (NYHA) classification (P = .001), lower extremity edema (P = .001), presence of an S3 (P = .02), hyponatremia (P = .02). elevated blood urea nitrogen (BUN) (P = .002), atrial fibrillation (P = .001), diabetes mellitus (P = .02), and obstructive sleep apnea (P = .009). Conclusions: Heart failure patients with the lowest LVEF or the highest heart rate at baseline had the greatest gain in LVEF after treatment with carvedilol. Patients with ischemic cardiomyopathy derived less benefit. Patients with clinical evidence of decompensated heart failure were at greater risk for hospitalization after initiation of carvedilol therapy.
引用
收藏
页码:4 / 12
页数:9
相关论文
共 21 条
[1]
Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation [J].
Aaronson, KD ;
Schwartz, JS ;
Chen, TM ;
Wong, KL ;
Goin, JE ;
Mancini, DM .
CIRCULATION, 1997, 95 (12) :2660-2667
[2]
Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol [J].
Andersson, B ;
Strömblad, SO ;
Lomsky, M ;
Waagstein, F .
EUROPEAN HEART JOURNAL, 1999, 20 (08) :575-583
[3]
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure [J].
Bristow, MR ;
Gilbert, EM ;
Abraham, WT ;
Adams, KF ;
Fowler, MB ;
Hershberger, RE ;
Kubo, SH ;
Narahara, KA ;
Ingersoll, H ;
Krueger, S ;
Young, S ;
Shusterman, N .
CIRCULATION, 1996, 94 (11) :2807-2816
[4]
DIFFERENCES IN BETA-ADRENERGIC NEUROEFFECTOR MECHANISMS IN ISCHEMIC VERSUS IDIOPATHIC DILATED CARDIOMYOPATHY [J].
BRISTOW, MR ;
ANDERSON, FL ;
PORT, JD ;
SKERL, L ;
HERSHBERGER, RE ;
LARRABEE, P ;
OCONNELL, JB ;
RENLUND, DG ;
VOLKMAN, K ;
MURRAY, J ;
FELDMAN, AM .
CIRCULATION, 1991, 84 (03) :1024-1039
[5]
PLASMA NOREPINEPHRINE AS A GUIDE TO PROGNOSIS IN PATIENTS WITH CHRONIC CONGESTIVE HEART-FAILURE [J].
COHN, JN ;
LEVINE, TB ;
OLIVARI, MT ;
GARBERG, V ;
LURA, D ;
FRANCIS, GS ;
SIMON, AB ;
RECTOR, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (13) :819-823
[6]
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure [J].
Colucci, WS ;
Packer, M ;
Bristow, MR ;
Gilbert, EM ;
Cohn, JN ;
Fowler, MB ;
Krueger, SK ;
Hershberger, R ;
Uretsky, BF ;
Bowers, JA ;
SacknerBernstein, JD ;
Young, ST ;
Holcslaw, TL ;
Lukas, MA .
CIRCULATION, 1996, 94 (11) :2800-2806
[7]
VALUE OF CARVEDILOL IN CONGESTIVE-HEART-FAILURE SECONDARY TO CORONARY-ARTERY DISEASE [J].
DASGUPTA, P ;
BROADHURST, P ;
RAFTERY, EB ;
LAHIRI, A .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (15) :1118-1123
[8]
Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart [J].
Gilbert, EM ;
Abraham, WT ;
Olsen, S ;
Hattler, B ;
White, M ;
Mealy, P ;
Larrabee, P ;
Bristow, MR .
CIRCULATION, 1996, 94 (11) :2817-2825
[9]
TIME-COURSE OF IMPROVEMENT IN LEFT-VENTRICULAR FUNCTION, MASS AND GEOMETRY IN PATIENTS WITH CONGESTIVE-HEART-FAILURE TREATED WITH BETA-ADRENERGIC-BLOCKADE [J].
HALL, SA ;
CIGARROA, CG ;
MARCOUX, L ;
RISSER, RC ;
GRAYBURN, PA ;
EICHHORN, EJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 25 (05) :1154-1161
[10]
Hjalmarson Å, 1999, LANCET, V353, P2001